China NT Pharma Group Company Limited has issued a clarification regarding its major transaction involving the acquisition of 100% of the issued shares in target companies, which includes the issuance of consideration shares under a specific mandate. The company has corrected the financial figures disclosed in a previous announcement dated April 28, 2025. The figures for the financial information related to the PRC Operating Company for the years ending December 31, 2023, and December 31, 2024, should be reflected in RMB, not thousands of RMB as previously stated. The revised figures show a revenue of RMB 2,437,639 for 2023 and RMB 1,810,151 for 2024, with losses before and after taxation also updated accordingly. Other details of the transaction remain unchanged.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。